Davidson Michael H. 4

What Happened

• Michael H. Davidson, CEO of NewAmsterdam Pharma Co. N.V., exercised stock options and sold the resulting shares in open-market transactions between Feb 24–26, 2026. He exercised a total of 306,293 option-based shares (64,708 on Feb 24; 58,253 on Feb 25; 183,332 on Feb 26) and sold the same number of ordinary shares.
• The sales totaled 306,293 shares for aggregate proceeds of approximately $10,575,092 (weighted averages by day/prices reported: $35.43–$36.74 ranges across trades; reported per-trade totals: Feb 24 ≈ $2.34M, Feb 25 ≈ $2.06M, Feb 26 ≈ $6.18M).
• These filings show exercises (derivative code M) followed by sales (code S) of the same share counts — consistent with an exercise plus immediate sale (commonly a cashless exercise). The option exercise price is EUR 1.16392 per share.

Key Details

• Transaction dates: Feb 24–26, 2026. Sales weighted-average prices and per-day totals:
  • Feb 24: 64,708 shares sold (split entries) — ~$2,338,943 (prices ranged ≈ $35.43–$36.42)
  • Feb 25: 58,253 shares sold (split entries) — ~$2,056,175 (prices ranged ≈ $34.57–$36.74)
  • Feb 26: 183,332 shares sold (split entries) — ~$6,179,974 (prices ranged ≈ $33.34–$34.82)
• Total sold: 306,293 shares for ~$10.6M.
• Notable footnotes:
  • F1: Exercise price = EUR 1.16392.
  • F10: Options were granted Nov 22, 2022 (replacement of a July 6, 2021 grant); vesting schedule described (25% vested Aug 1, 2021; remainder monthly over 3 years subject to continued service).
  • F2–F8: Reported prices are weighted averages; per-trade sale-price ranges are provided in the filing.
  • F9: Separately, 285,715 ordinary shares were transferred by Davidson into the "Michael H. Davidson 2026 Grantor Retained Annuity Trust" (GRAT) on Feb 26, 2026; that transfer was exempt from Section 16 reporting under Rule 16a-13. Davidson is sole annuitant and trustee.
• Shares owned after these transactions: not specified in the provided excerpt of the filing.
• Filing timeliness: filing date Feb 26, 2026 (covers transactions Feb 24–26); the filing itself does not indicate a late/untimely status in the provided data.

Context

• For retail investors: these transactions reflect option exercises followed by open-market sales that converted vested equity into cash for the insider. Such exercises plus immediate sales are common for liquidity (and tax) management and do not by themselves indicate the insider’s view of the company’s long-term prospects.
• The GRAT transfer is a non-sale estate-planning action and was reported as exempt from Section 16 obligations; transfers into trusts/gifts are generally not market-sentiment signals.